![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AP5B1 |
Gene summary for AP5B1 |
![]() |
Gene information | Species | Human | Gene symbol | AP5B1 | Gene ID | 91056 |
Gene name | adaptor related protein complex 5 subunit beta 1 | |
Gene Alias | AP-5 | |
Cytomap | 11q13.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q2VPB7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
91056 | AP5B1 | HCC1_Meng | Human | Liver | HCC | 1.61e-12 | 8.74e-03 | 0.0246 |
91056 | AP5B1 | HCC2_Meng | Human | Liver | HCC | 7.87e-04 | 3.55e-02 | 0.0107 |
91056 | AP5B1 | HCC1 | Human | Liver | HCC | 1.90e-12 | 1.03e+00 | 0.5336 |
91056 | AP5B1 | HCC2 | Human | Liver | HCC | 1.40e-20 | 1.58e+00 | 0.5341 |
91056 | AP5B1 | HCC5 | Human | Liver | HCC | 1.26e-19 | 1.54e+00 | 0.4932 |
91056 | AP5B1 | S027 | Human | Liver | HCC | 3.70e-02 | 2.12e-01 | 0.2446 |
91056 | AP5B1 | S028 | Human | Liver | HCC | 6.96e-07 | 2.52e-01 | 0.2503 |
91056 | AP5B1 | S029 | Human | Liver | HCC | 9.47e-05 | 2.72e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001619721 | Liver | HCC | endosomal transport | 154/7958 | 230/18723 | 4.74e-14 | 2.95e-12 | 154 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AP5B1 | SNV | Missense_Mutation | c.1114G>A | p.Val372Ile | p.V372I | Q2VPB7 | protein_coding | tolerated(0.35) | benign(0) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
AP5B1 | SNV | Missense_Mutation | c.2393N>C | p.Val798Ala | p.V798A | Q2VPB7 | protein_coding | deleterious(0.01) | benign(0.23) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
AP5B1 | SNV | Missense_Mutation | c.1835C>T | p.Ala612Val | p.A612V | Q2VPB7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A15K-06 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
AP5B1 | SNV | Missense_Mutation | novel | c.1385N>T | p.Ala462Val | p.A462V | Q2VPB7 | protein_coding | tolerated(0.26) | benign(0.093) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AP5B1 | SNV | Missense_Mutation | novel | c.1034N>T | p.Ala345Val | p.A345V | Q2VPB7 | protein_coding | tolerated(0.12) | benign(0.344) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AP5B1 | SNV | Missense_Mutation | c.1372N>T | p.Pro458Ser | p.P458S | Q2VPB7 | protein_coding | tolerated(0.3) | probably_damaging(0.988) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
AP5B1 | SNV | Missense_Mutation | c.1372N>T | p.Pro458Ser | p.P458S | Q2VPB7 | protein_coding | tolerated(0.3) | probably_damaging(0.988) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
AP5B1 | SNV | Missense_Mutation | novel | c.1462C>T | p.His488Tyr | p.H488Y | Q2VPB7 | protein_coding | tolerated(0.07) | possibly_damaging(0.447) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AP5B1 | SNV | Missense_Mutation | c.1659G>T | p.Gln553His | p.Q553H | Q2VPB7 | protein_coding | deleterious(0.03) | benign(0.01) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
AP5B1 | SNV | Missense_Mutation | novel | c.2125G>A | p.Ala709Thr | p.A709T | Q2VPB7 | protein_coding | tolerated(0.13) | benign(0.167) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |